drugset
drugset / Trial / NCT06963398

A Study of HS-10529 in KRAS G12D Patients With Advanced Solid Tumors

NCT06963398 ↗

Phase 1 Not yet recruiting 520 enrolled Jiangsu Hansoh Pharmaceutical Co., Ltd.
NaSingle-groupOpen-labelTreatment

Summary

HS-10529 is an oral, highly selective, small molecular inhibitor of KRAS G12D. This study will evaluate the safety, tolerability, pharmacokinetics and clinical activity of HS-10529 in KRAS G12D patients with advanced solid tumors.

Timeline

Start
2025-05-15
Primary completion
2029-04-30
Completion
2029-08-30

Drugs

EvaluationDrugModalityDoseRoute
Subject HS-10529 Small molecule — Oral

Indications

cancer